Interview: New Chugai CEO Lays Course As He Takes Reins (Part 2).
Executive Summary
Chugai's new CEO Tatsuro Kosaka took up his position in March and is charged with taking the major Japanese company through the next stage of development as key new products reach the global market and others begin to face generic competition. In this second and final part of an exclusive interview with Scrip, he talks about major mid-term growth prospects, recent pricing reforms in Japan, and how Chugai is tapping into novel disruptive technologies.
You may also be interested in...
Legal Challenge To First Japan Rituxan Biosimilar Dismissed
First Japan legal ruling means biosimilar competition can continue to gnaw away at Rituxan, at least for now, as Chugai faces rising challenges to its mature oncology portfolio.
Herceptin, Enbrel Face First Biosimilar Rivals In Japan But Outlook Uncertain
The first biosimilar versions in Japan of two major biologic therapies, Herceptin and Enbrel, have been awarded reimbursement prices, clearing the way for launch, but commercial prospects remain uncertain.
Herceptin, Enbrel Face First Biosimilar Rivals In Japan But Outlook Uncertain
The first biosimilar versions in Japan of two major biologic therapies, Herceptin and Enbrel, have been awarded reimbursement prices, clearing the way for launch, but commercial prospects remain uncertain.